HUTCHMED (China) Limited HCM

Updated: 15 Jun 2026

NASDAQ | Biotech | Biotech, oncology and immunology

No signal published yet

We already track HUTCHMED and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow HUTCHMED free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotech, oncology and immunology
We're already tracking HUTCHMED (China) Limited — here are the latest events we've registered

Recent News

  • On June 12, 2026, HUTCHMED announced positive Phase III results for sovleplenib in treating warm antibody autoimmune hemolytic anemia (wAIHA) at the EHA Congress. The study met its primary endpoint with a 66% durable response rate compared to 15% for placebo, supporting the company's New Drug Application currently under priority review in China.

What Firelda Watch includes for HUTCHMED (China) Limited

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of HUTCHMED (China) Limited will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow HUTCHMED (China) Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow HUTCHMED free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

HUTCHMED (China) Limited HCM
HUTCHMED — follow and we'll monitor it
Follow HUTCHMED free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.